Gilead Sciences, Inc. (NASDAQ:GILD) in partnership with the GlaxoSmithKline plc (ADR) (NYSE:GSK) today has announced their plans for an international clinical trial to study the combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH). The study will be called AMBITION and it derives its name from AMBrIsentan and Tadalafil in subjects with pulmonary arterial hypertensION. The clinical trial will be a double blind, multicenter study with more than 300 PAH patients who will be receiving a randomized combination of ambrisentan and tadalafil or monotherapy. http://www.favstocks.com/gilead-sciences...

Currently both the companies are working with the regulatory agencies and PAH research communities to finalize the details of their study. Enrollment for the study is expected to begin in 2010 after both the companies finalize and get approvals from regulatory agencies.